Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

FDA approves mirvetuximab soravtansine-gynx (Elahere)

March 25, 2024 2:19 PM | Katy Monaco (Administrator)

Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected based on an FDA-approved test. Mirvetuximab soravtansine-gynx previously received accelerated approval for this indication. Read More.

Full prescribing information for Elahere will be posted here.


860 Winter Street, Waltham, MA, 02451


tel: 781.434.7329

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software